BioSpace News Archive

Exact Sciences Corp. announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020.

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ :OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that the first patient for the company’s Phase 1b oncology clinical trial has been enrolled at the Cross Cancer Institute (Edmonton, Alberta) under Principal Investigator Dr. Jennifer Spratlin.

Kaiser Permanente is again among the highest rated health plans as indicated in the Centers for Medicare & Medicaid Services annual Star Ratings for 2021, providing expert medicine, seamless care, and outstanding service to its Medicare members.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that positive results from the Phase 2 DISCOVERY study evaluating pegcetacoplan, a targeted C3 therapy, in patients with C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week on October 22, 2020.

As healthcare facilities look for new and innovative ways to battle multi-drug resistant organisms that can pose a risk to patient safety, Urosurgical Center of Richmond has taken a leap into the future with a LightStrike Germ-Zapping Robot named Rosie that destroys hard-to-kill viruses, bacteria and superbugs in hard-to-clean places.

Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, today announced positive interim results from their first-in-human (FIH) trial of splanchnic ablation for volume management, or SAVM, using the Satera™ Ablation System.

The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “Protein Degradation Drug Discovery”.

The Parkinson Foundation of the National Capital Area (PFNCA) will host its annual awareness and fundraising walk – Walk Off Parkinson’s – virtually on Oct. 14 and Oct. 20 , 2020. The program, which starts at 6:30 p.m. ET each day, features educational and inspirational content from 18 doctors who are Movement Disorder Specialists

careMESH today announced that Gustavo Bonany has been appointed as chief technology officer (CTO).